Phenylpiracetam occupies a legal gray zone in most countries. It is not a controlled substance in the United States, but it is not approved as a medication or dietary supplement either. The exact legal status varies significantly depending on where you live, and in some countries it requires a prescription or is banned from sale entirely.
United States: Unregulated but Not Approved
Phenylpiracetam is not scheduled under the Controlled Substances Act, which means possessing it is not a criminal offense. However, the FDA has not approved it for any medical use, and it does not qualify as a dietary supplement because it is a synthetic compound rather than a vitamin, mineral, herb, or amino acid. This creates an unusual situation: you can legally buy and possess it, but companies selling it cannot legally market it as a supplement or make health claims.
In practice, phenylpiracetam has become harder to find from U.S.-based vendors in recent years. The original branded product, Phenotropil, was discontinued by its Russian manufacturer, and the overall supply chain for the compound has thinned considerably. Some retailers have stopped carrying it altogether.
If you order phenylpiracetam from overseas, U.S. Customs and Border Protection generally allows medications for personal use in quantities of no more than a 90-day supply. That said, the FDA can legally confiscate any product it has not approved for use in the United States, so importing it carries some risk of seizure at the border, even if criminal penalties are unlikely.
Russia: Prescription Medication
Russia is the one country where phenylpiracetam has a clear, defined pharmaceutical status. It was developed at the Research Institute of Cosmic Medicine as a stimulant and stress-protective agent, originally intended for cosmonauts. It is available only by prescription at a typical dose of 100 to 200 mg per day, prescribed for conditions involving memory impairment, difficulty concentrating, low mood, and reduced physical performance. Outside of Russia, no health authority in the EU or Australia has authorized it for human use.
Australia: Prescription-Only (Schedule 4)
Australia’s Therapeutic Goods Administration explicitly classifies phenylpiracetam as a Schedule 4 substance, meaning it is prescription-only. This scheduling took effect in mid-2019 as part of a broader move to clarify the status of the entire racetam family. Before that decision, phenylpiracetam was technically captured under existing racetam scheduling rules, but the TGA added a specific entry to remove any ambiguity. You cannot legally buy or import phenylpiracetam in Australia without a prescription, and since no Australian doctor can prescribe it for an approved indication, obtaining it legally is effectively impossible for most people.
European Union: Not Authorized for Sale
No EU member state has approved phenylpiracetam as a medicine. A 2025 market surveillance study by official medicines control laboratories across Europe described it plainly: phenylpiracetam is “not authorised for human use by any health authority in the EU.” Substantial quantities of raw phenylpiracetam powder have been identified circulating through unofficial channels, but selling it for human consumption is illegal. Individual EU countries can impose additional restrictions through their own national laws, so the exact consequences of buying or possessing it vary from one country to the next.
United Kingdom: A Legal Gray Area
The UK’s 2016 Psychoactive Substances Act banned the sale, distribution, and importation of psychoactive substances not covered by other laws, unless specifically exempted. Phenylpiracetam has been shown to act on central nervous system receptors, but as of the most recent assessment, it has not been formally tested for psychoactivity under the PSA’s criteria. That means it cannot be definitively considered banned under the Act. In practical terms, this leaves phenylpiracetam in limbo: it is not clearly legal to sell, but it has not been formally prohibited either. Possession for personal use is not an offense under the PSA regardless.
New Zealand: Moving Toward Prescription Status
New Zealand’s medicines regulator, Medsafe, has recommended that phenylpiracetam (listed under its international nonproprietary name, fonturacetam) be classified as a prescription medicine. Previously, racetam analogs fell through the cracks because New Zealand’s scheduling only covered the parent compounds and their esters or salts, not structurally related analogs. The proposed change would add fonturacetam and its stereoisomers to Schedule 1 of the Medicines Regulations, making it illegal to sell without a prescription.
Banned in Competitive Sports
Regardless of its consumer legal status, phenylpiracetam is prohibited in all competitive sports governed by the World Anti-Doping Agency. It falls under category S6.A (non-specified stimulants) on the WADA Prohibited List. The ban applies during competition, and any trace found in an athlete’s blood or urine sample constitutes a doping violation. Phenylpiracetam actually holds a distinction here: in 1998, the International Olympic Committee made it the first nootropic ever banned in sport, after research showed that a 100 mg dose could measurably improve exercise performance. Several Olympic athletes have been sanctioned for testing positive.
What About Phenylpiracetam Hydrazide?
Some vendors sell a modified version called phenylpiracetam hydrazide, sometimes marketed as a legal alternative. These analog compounds exist in an even murkier regulatory space. In countries like New Zealand, regulators have specifically noted that analogs of scheduled racetams were not automatically captured by existing rules, which is precisely why they moved to schedule them individually. Whether a hydrazide variant falls under a given country’s racetam scheduling depends on how broadly that country defines its chemical analog laws. In the U.S., where the parent compound itself is unscheduled, the hydrazide version faces no additional legal barriers. In Australia or the EU, it may or may not be captured under broader scheduling language, and the safest assumption is that regulators will treat it the same as the parent compound.
The bottom line is that phenylpiracetam is not a controlled substance in most Western countries, but “not controlled” does not mean “approved” or “legal to sell.” The global trend is toward tighter regulation: Australia has scheduled it, New Zealand is following suit, and the EU treats it as unauthorized. If you are buying it for personal use in the U.S. or UK, you are unlikely to face criminal consequences, but you are also buying a product with no quality oversight, no approved manufacturing standard, and a shrinking number of reliable sources.